Sodium sulfacyl, eye drops 20% 5 ml

Pharmacological properties
Pharmacodynamics
Antimicrobial bacteriostatic agent, sulfonamide. Mechanism of action is due to competitive antagonism with para-aminobenzoic acid and inhibition of dihydropteroat synthetase, disruption of tetrahydrofolic acid synthesis, necessary for purines and pyrimidines synthesis.
Active against Gram-positive and Gram-negative cocci, Escherichia coli, Shigella spp, Vibrio cholerae, Clostridium perfringens, Bacillus anthracis, Corynebacterium diphtheriae, Yersinia pestis, Chlamydia spp, Actinomyces israelii, Toxoplasma gondii.

Pharmacokinetics
When applied topically, the maximum concentration (Cmax) of sulfonamides in cornea (about 3 mg/ml), anterior chamber humour (about 0.5 mg/ml) and iris (about 0.1 mg/ml) is reached within the first 30 minutes after application. Some amount (less than 0.5 mg/ml) persists in the eyeball tissues for 3-4 hours. Penetration of sulfonamides increases with corneal epithelium damage.

Indications

In the complex treatment of diseases of the eyelids, conjunctiva, cornea, anterior segment of the choroid and lacrimal ducts caused by microorganisms sensitive to sulfacetamide. For the prevention of infectious complications in the complex treatment of burns and injuries to the visual organs.

Pharmacological effect

Pharmacotherapeutic group:
antimicrobial agent – ​​sulfanilamide.

ATX code: S01AB04

Pharmacological properties

Pharmacodynamics
Antimicrobial bacteriostatic agent, sulfanilamide. The mechanism of action is due to competitive antagonism with para-aminobenzoic acid and inhibition of dihydropteroate synthetase, disruption of the synthesis of tetrahydrofolic acid, necessary for the synthesis of purines and pyrimidines.
Active against gram-positive and gram-negative cocci, Escherichia coli, Shigella spp., Vibrio cholerae, Clostridium perfringens, Bacillus anthracis, Corynebacterium diphtheriae, Yersinia pestis, Chlamydia spp., Actinomyces israelii, Toxoplasma gondii.

Pharmacokinetics
When applied topically, the maximum concentration (Cmax) of sulfonamides in the cornea (about 3 mg/ml), anterior chamber fluid (about 0.5 mg/ml) and iris (about 0.1 mg/ml) is achieved within the first 30 minutes after application. A certain amount (less than 0.5 mg/ml) remains in the tissues of the eyeball for 3-4 hours. When the corneal epithelium is damaged, the penetration of sulfonamides increases.

Special instructions

Patients hypersensitive to furosemide, thiazide diuretics, sulfonylureas, or carbonic anhydrase inhibitors may be hypersensitive to sulfacetamide. After opening, use within 30 days.

The ability to influence the speed of reactions when driving vehicles or working with other mechanisms
If, after using the drug, the clarity of visual perception is temporarily reduced in a patient, until it is restored, it is not recommended to drive a car or engage in activities that require increased attention and reaction.

Active ingredient

Sulfacetamide

Composition

Active substance:
sulfacetamide – 200 mg
Excipients:
sodium thiosulfate – 1 mg
hydrochloric acid (1 M solution of hydrochloric acid) – up to pH 8.5
water for injection – up to 1 ml

Pregnancy

There is no sufficient experience with the use of the drug during pregnancy and breastfeeding. It is possible to use sulfacetamide for the treatment of pregnant and nursing mothers as prescribed by the attending physician, if the expected therapeutic effect exceeds the risk of developing possible side effects.

Contraindications

Hypersensitivity to the components of the drug.

Side Effects

Burning, lacrimation, pain, itching in the eyes, transient blurred vision after instillation, allergic reactions.

Interaction

Combined use with procaine and tetracaine reduces the bacteriostatic effect. Incompatibility with silver salts.

Overdose

There are no data on drug overdose.

Storage conditions

In a place protected from light at a temperature of 2 to 15 °C.
Keep out of the reach of children.

Shelf life

2 years.
After opening, use within 30 days.
Do not use after expiration date.

Manufacturer

Update of PFC JSC, Russia